Haemonetics Corporation (HAE): Price and Financial Metrics

Haemonetics Corporation (HAE): $48.39

-0.67 (-1.37%)

POWR Rating

Component Grades














  • HAE scores best on the Growth dimension, with a Growth rank ahead of 81.87% of US stocks.
  • HAE's strongest trending metric is Growth; it's been moving up over the last 163 days.
  • HAE's current lowest rank is in the Momentum metric (where it is better than 14.09% of US stocks).

HAE Stock Summary

  • Haemonetics Corp's stock had its IPO on May 10, 1991, making it an older stock than 83.42% of US equities in our set.
  • With a price/earnings ratio of 82.33, Haemonetics Corp P/E ratio is greater than that of about 91.71% of stocks in our set with positive earnings.
  • With a year-over-year growth in debt of 68.27%, Haemonetics Corp's debt growth rate surpasses 87.96% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Haemonetics Corp are PMD, LNN, AMEH, ATRI, and ICUI.
  • HAE's SEC filings can be seen here. And to visit Haemonetics Corp's official web site, go to www.haemonetics.com.

HAE Valuation Summary

  • HAE's price/sales ratio is 3.5; this is 7.89% lower than that of the median Healthcare stock.
  • HAE's price/sales ratio has moved up 0.4 over the prior 243 months.
  • Over the past 243 months, HAE's EV/EBIT ratio has gone up 9.2.

Below are key valuation metrics over time for HAE.

Stock Date P/S P/B P/E EV/EBIT
HAE 2021-08-31 3.5 4.7 49.7 48.0
HAE 2021-08-30 3.5 4.7 48.9 47.4
HAE 2021-08-27 3.5 4.6 48.7 47.2
HAE 2021-08-26 3.4 4.5 47.1 45.9
HAE 2021-08-25 3.4 4.5 47.5 46.2
HAE 2021-08-24 3.5 4.6 48.3 46.9

HAE Growth Metrics

    The 3 year net cashflow from operations growth rate now stands at 30.7%.
  • Its 4 year net income to common stockholders growth rate is now at 237.69%.
  • Its year over year price growth rate is now at -47.87%.
HAE's revenue has moved down $18,011,000 over the prior 33 months.

The table below shows HAE's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 933.825 109.618 31.243
2021-06-30 903.414 95.313 64.488
2021-03-31 870.463 108.805 79.469
2020-12-31 883.926 153.664 108.134
2020-09-30 902.525 166.655 106.147
2020-06-30 945.605 167.401 95.532

HAE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • HAE has a Quality Grade of C, ranking ahead of 50% of graded US stocks.
  • HAE's asset turnover comes in at 0.569 -- ranking 76th of 186 Medical Equipment stocks.
  • CRY, CTSO, and CSII are the stocks whose asset turnover ratios are most correlated with HAE.

The table below shows HAE's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-07-03 0.569 0.460 0.072
2021-04-03 0.581 0.457 0.090
2020-12-26 0.650 0.486 0.150
2020-09-26 0.674 0.485 0.151
2020-06-27 0.738 0.485 0.142
2020-03-28 0.798 0.490 0.116

HAE Price Target

For more insight on analysts targets of HAE, see our HAE price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $79.25 Average Broker Recommendation 1.38 (Strong Buy)

HAE Stock Price Chart Interactive Chart >

Price chart for HAE

HAE Price/Volume Stats

Current price $48.39 52-week high $142.11
Prev. close $50.33 52-week low $48.07
Day low $48.07 Volume 12,465
Day high $48.98 Avg. volume 476,679
50-day MA $53.58 Dividend yield N/A
200-day MA $62.80 Market Cap 2.47B

Haemonetics Corporation (HAE) Company Bio

Haemonetics designs, manufactures, and markets blood management solutions. The Company serves in three markets, such as manufacturers of plasma-derived pharmaceuticals, blood collectors, and hospitals. The company was founded in 1971 and is based in Braintree, Massachusetts.

HAE Latest News Stream

Event/Time News Detail
Loading, please wait...

HAE Latest Social Stream

Loading social stream, please wait...

View Full HAE Social Stream

Latest HAE News From Around the Web

Below are the latest news stories about Haemonetics Corp that investors may wish to consider to help them evaluate HAE as an investment opportunity.

Haemonetics Sets Date for Publishing Third Quarter Fiscal Year 2022 Results: February 8, 2022

Haemonetics Corporation (NYSE: HAE) announced that the Company intends to publish third quarter fiscal year 2022 financial results at 6:00 am EST on Tuesday, February 8, 2022. The Company will hold a conference call with investors and analysts to discuss results and answer questions at 8:00 am EST on February 8, 2022.

Yahoo | January 5, 2022

Managed Portfolio Series Buys Haemonetics Corp, Sprouts Farmers Market Inc, Patterson Inc, ...

Investment company Managed Portfolio Series (Current Portfolio) buys Haemonetics Corp, Sprouts Farmers Market Inc, Patterson Inc, TripAdvisor Inc, Frontdoor Inc, sells Healthcare Services Group Inc, Jefferies Financial Group Inc, Urban Outfitters Inc, Jones Lang LaSalle Inc, Gildan Activewear Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Managed Portfolio Series.

Yahoo | December 28, 2021

Thromboelastography Market See Incredible Growth 2021-2028 | Haemonetics Corporation, Instrumentation Laboratory, Framar Hemologix srl, Medirox AB

The Thromboelastography Market report focus on the current trends of the request along with detailed analysis which provides data regarding this request rate, and it also predicts the unborn request growth rate. The Thromboelastography Market study includes exploration on the

OpenPR | December 23, 2021

Here's Why You Should Retain Haemonetics (HAE) Stocks for Now

Investors are optimistic about Haemonetics (HAE) on a strong recovery across businesses, mainly at Hospital, and the initial Plasma Persona rollouts.

Yahoo | December 20, 2021

Worldwide Blood Transfusion Devices Industry to 2026 - by Product, Blood Component, End-user and Region - ResearchAndMarkets.com

The "Global Blood Transfusion Devices Market, By Product (Apheresis Systems, Infusion Devices, Blood Warmers, Venous Access Devices, Filters, Others), By Blood Component (Whole Blood, Plasma, RBC, Others), By End User, By Region, Forecast & Opportunities, 2026" report has been added to ResearchAndMarkets.com''s offering. The global blood transfusion devices market is expected to grow at a CAGR of around 6% during the forecast period. Companies Mentioned Fresenius Kabi AG Grifols SA Terumo Corporation B Braun Melsungen AG Becton, Dickinson, and Company Immucor Inc Haemonetics Corporation Kaneka Corporation Macopharma SA Tenko International Group Corp The global blood transfusion devices market is driven by upsurge in count of surgical procedures being carried out across the globe. Moreov...

Benzinga | December 17, 2021

Read More 'HAE' Stories Here

HAE Price Returns

1-mo N/A
3-mo -32.41%
6-mo -18.80%
1-year -58.61%
3-year -50.12%
5-year 21.95%
YTD -8.77%
2021 -55.33%
2020 3.35%
2019 14.84%
2018 72.26%
2017 44.48%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.8042 seconds.